Article Abstract

Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia

Authors: Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku

Abstract

Prolyl hydroxylase domain (PHD) inhibitors are orally bioavailable small-molecule compounds that activate hypoxia inducible factor (HIF). HIF is a master transcription factor for regulating the cellular adaptive response to hypoxia. Erythropoietin (EPO), a hormone essential for red blood cell production, is one of the target genes of HIF. PHD inhibitors have been developed for the treatment of anemia with chronic kidney disease (CKD).

Article Options

Download Citation